Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of JNJ-55375515 in Healthy Men
NCT03405441Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-55375515 in major depressive disorder (MDD) and schizophrenia (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability. Started Jan 2018; status: completed.
02
Drugs
JNJ-55375515
03
Conditions
major depressive disorder (MDD)schizophrenia
Beyond the preview
Go deeper on NCT03405441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03405441.